FibroGen, Inc(FGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

FGEN FibroGen, Inc

休市中 12-19 16:00:00 EST

8.60

+0.28

+3.37%

盘后8.52

-0.08-0.93%

19:21 EST

最高8.92	最低8.35	成交量3.25万
今开8.35	昨收8.32	日振幅6.85%
总市值3,479万	流通市值3,116万	总股本404.54万
成交额28.07万	换手率0.90%	流通股本362.37万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"FGEN","market":"US","secType":"STK","nameCN":"FibroGen, Inc","latestPrice":8.6,"timestamp":1766178000000,"preClose":8.32,"halted":0,"volume":32520,"hourTrading":{"tag":"盘后","latestPrice":8.52,"preClose":8.6,"latestTime":"19:21 EST","volume":136,"amount":1162.72,"timestamp":1766190060386},"delay":0,"floatShares":3623701,"shares":4045445,"eps":53.37957,"marketStatus":"休市中","change":0.28,"latestTime":"12-19 16:00:00 EST","open":8.35,"high":8.92,"low":8.35,"amount":280686.16872,"amplitude":0.06851,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":53.37957,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":8.32,"preHourTrading":{"tag":"盘前","latestPrice":8.34,"preClose":8.32,"latestTime":"08:00 EST","volume":21,"amount":175.14,"timestamp":1766149202744},"postHourTrading":{"tag":"盘后","latestPrice":8.52,"preClose":8.6,"latestTime":"19:21 EST","volume":136,"amount":1162.72,"timestamp":1766190060386},"volumeRatio":0.33176801298283953,"impliedVol":1.651,"impliedVolPercentile":0.9587},"requestUrl":"/m/hq/s/FGEN","defaultTab":"news","newsList":[{"id":"1142804214","title":"Roxadustat获得美国食品药品监督管理局对骨髓增生异常综合症的孤儿药认证","url":"https://stock-news.laohu8.com/highlight/detail?id=1142804214","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142804214?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:03","pubTimestamp":1765800205,"startTime":"0","endTime":"0","summary":"Roxadustat获得美国食品药品监督管理局对骨髓增生异常综合症的孤儿药认证","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","FGEN","BK4139"],"gpt_icon":0},{"id":"2577844103","title":"珐博进盘中异动 早盘股价大涨5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577844103","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577844103?lang=zh_cn&edition=full","pubTime":"2025-10-20 22:48","pubTimestamp":1760971709,"startTime":"0","endTime":"0","summary":"北京时间2025年10月20日22时48分，珐博进股票出现波动，股价快速拉升5.49%。截至发稿，该股报10.95美元/股，成交量7878股，换手率0.19%，振幅6.84%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。珐博进股票所在的生物技术行业中，整体涨幅为0.18%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020224829a46a6f77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020224829a46a6f77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","FGEN","BK4139"],"gpt_icon":0},{"id":"1122529188","title":"FibroGen, Inc：FG-3246联合Enzalutamide治疗转移性去势抵抗性前列腺癌患者的关键试验结果预计2025年第四季度发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1122529188","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122529188?lang=zh_cn&edition=full","pubTime":"2025-09-24 19:07","pubTimestamp":1758712034,"startTime":"0","endTime":"0","summary":"FibroGen, Inc宣布，其在研药物FG-3246与Enzalutamide联合治疗转移性去势抵抗性前列腺癌(mCRPC)患者的临床试验顶线结果，预计将于2025年第四季度公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN","BK4139","BK4505"],"gpt_icon":0},{"id":"1169582552","title":"FibroGen启动FG-3246的2期单药疗法试验，这是一款针对转移性去势抵抗性前列腺癌的首创CD46靶向抗体药物偶联物","url":"https://stock-news.laohu8.com/highlight/detail?id=1169582552","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169582552?lang=zh_cn&edition=full","pubTime":"2025-09-24 19:01","pubTimestamp":1758711681,"startTime":"0","endTime":"0","summary":"FibroGen宣布启动FG-3246的2期单药疗法临床试验，该药物是一款同类首创的CD46靶向抗体药物偶联物，用于治疗转移性去势抵抗性前列腺癌患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN","BK4139","BK4505"],"gpt_icon":0},{"id":"2558664726","title":"珐博进盘中异动 下午盘股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558664726","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558664726?lang=zh_cn&edition=full","pubTime":"2025-08-12 01:17","pubTimestamp":1754932620,"startTime":"0","endTime":"0","summary":"北京时间2025年08月12日01时17分，珐博进股票出现异动，股价大幅下挫5.00%。截至发稿，该股报8.27美元/股，成交量2.1407万股，换手率0.53%，振幅5.74%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。珐博进股票所在的生物技术行业中，整体跌幅为0.30%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081201170194dd11c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081201170194dd11c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","FGEN","BK4139"],"gpt_icon":0},{"id":"2558576918","title":"珐博进盘中异动 急速上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558576918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558576918?lang=zh_cn&edition=full","pubTime":"2025-08-09 00:22","pubTimestamp":1754670156,"startTime":"0","endTime":"0","summary":"北京时间2025年08月09日00时22分，珐博进股票出现异动，股价急速上涨5.04%。截至发稿，该股报8.34美元/股，成交量3.1232万股，换手率0.77%，振幅6.68%。珐博进股票所在的生物技术行业中，整体跌幅为0.53%。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809002237a6db5ed2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809002237a6db5ed2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","FGEN"],"gpt_icon":0},{"id":"2557330437","title":"珐博进盘中异动 快速上涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557330437","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557330437?lang=zh_cn&edition=full","pubTime":"2025-08-07 03:39","pubTimestamp":1754509172,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日03时39分，珐博进股票出现异动，股价急速上涨5.05%。截至发稿，该股报7.26美元/股，成交量2.2854万股，换手率0.57%，振幅2.89%。珐博进股票所在的生物技术行业中，整体跌幅为0.22%。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080703393294d3fde4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080703393294d3fde4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","FGEN"],"gpt_icon":0},{"id":"2553988132","title":"珐博进7月22日成交额为16.47万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553988132","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553988132?lang=zh_cn&edition=full","pubTime":"2025-07-23 10:10","pubTimestamp":1753236609,"startTime":"0","endTime":"0","summary":"美东时间2025年7月22日，珐博进成交额为16.47万美元，成交额较昨日减少35.49%，当日成交量为2.19万股。珐博进于2025年7月22日涨1.98%，报7.71美元，该股过去5个交易日涨5.33%，年初至今跌41.81%，过去60日跌3.63%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723101011a45da5c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723101011a45da5c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","FGEN"],"gpt_icon":0},{"id":"2553283273","title":"珐博进7月21日成交额为25.52万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553283273","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553283273?lang=zh_cn&edition=full","pubTime":"2025-07-22 10:10","pubTimestamp":1753150204,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日，珐博进成交额为25.52万美元，成交额较昨日增加113.93%，当日成交量为3.33万股。珐博进于2025年7月21日跌1.18%，报7.56美元，该股过去5个交易日跌1.69%，年初至今跌42.94%，过去60日跌1.5%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722101013a45af56e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722101013a45af56e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","FGEN","BK4139"],"gpt_icon":0},{"id":"2552415613","title":"珐博进7月18日成交额为11.93万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552415613","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552415613?lang=zh_cn&edition=full","pubTime":"2025-07-19 10:05","pubTimestamp":1752890723,"startTime":"0","endTime":"0","summary":"美东时间2025年7月18日，珐博进成交额为11.93万美元，成交额较昨日减少65.48%，当日成交量为1.51万股。珐博进于2025年7月18日跌5.2%，报7.65美元，该股过去5个交易日涨6.99%，年初至今跌42.26%，过去60日涨2.0%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719100526a4549031&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719100526a4549031&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","FGEN","BK4139"],"gpt_icon":0},{"id":"2552436990","title":"珐博进盘中异动 股价大涨6.25%报7.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552436990","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552436990?lang=zh_cn&edition=full","pubTime":"2025-07-18 02:18","pubTimestamp":1752776309,"startTime":"0","endTime":"0","summary":"北京时间2025年07月18日02时18分，珐博进股票出现波动，股价急速上涨6.25%。截至发稿，该股报7.99美元/股，成交量2.1254万股，换手率0.53%，振幅6.91%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。珐博进股票所在的生物技术行业中，整体跌幅为0.04%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718021829a4519f20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718021829a4519f20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","FGEN","BK4139"],"gpt_icon":0},{"id":"2552740691","title":"珐博进7月16日成交额为22.90万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552740691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552740691?lang=zh_cn&edition=full","pubTime":"2025-07-17 10:06","pubTimestamp":1752717965,"startTime":"0","endTime":"0","summary":"美东时间2025年7月16日，珐博进成交额为22.90万美元，成交额较昨日增加52.11%，当日成交量为3.04万股。珐博进于2025年7月16日涨2.73%，报7.52美元，该股过去5个交易日涨21.49%，年初至今跌43.25%，过去60日涨5.17%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717100608a44fd9bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717100608a44fd9bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","FGEN"],"gpt_icon":0},{"id":"2551194817","title":"珐博进盘中异动 下午盘急速下挫5.98%报7.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551194817","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551194817?lang=zh_cn&edition=full","pubTime":"2025-07-16 02:55","pubTimestamp":1752605727,"startTime":"0","endTime":"0","summary":"北京时间2025年07月16日02时55分，珐博进股票出现异动，股价大幅下挫5.98%。截至发稿，该股报7.23美元/股，成交量1.3749万股，换手率0.34%，振幅6.63%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。珐博进股票所在的生物技术行业中，整体跌幅为1.24%。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071602552797a7637e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071602552797a7637e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FGEN","BK4139","BK4505"],"gpt_icon":0},{"id":"2551137671","title":"珐博进7月14日成交额为25.49万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551137671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551137671?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:10","pubTimestamp":1752545413,"startTime":"0","endTime":"0","summary":"美东时间2025年7月14日，珐博进成交额为25.49万美元，成交额较昨日减少42.27%，当日成交量为3.40万股。珐博进于2025年7月14日涨7.55%，报7.69美元，该股过去5个交易日涨43.2%，年初至今跌41.96%，过去60日涨3.92%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715101017a6a9ed55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715101017a6a9ed55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FGEN","BK4505","BK4139"],"gpt_icon":0},{"id":"2551180701","title":"珐博进盘中异动 股价大涨5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551180701","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551180701?lang=zh_cn&edition=full","pubTime":"2025-07-15 00:31","pubTimestamp":1752510691,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日00时31分，珐博进股票出现波动，股价快速拉升5.31%。截至发稿，该股报7.53美元/股，成交量1.4807万股，换手率0.37%，振幅6.49%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。珐博进股票所在的生物技术行业中，整体涨幅为0.57%。迄今为止，珐博进几乎所有的收入都来自其合作协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715003132a6a93499&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715003132a6a93499&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FGEN","BK4505","BK4139"],"gpt_icon":0},{"id":"2550606427","title":"珐博进7月10日成交额为162.77万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550606427","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550606427?lang=zh_cn&edition=full","pubTime":"2025-07-11 10:10","pubTimestamp":1752199816,"startTime":"0","endTime":"0","summary":"美东时间2025年7月10日，珐博进成交额为162.77万美元，成交额较昨日增加198.88%，当日成交量为22.80万股。珐博进于2025年7月10日涨18.74%，报7.35美元，该股过去5个交易日涨40.0%，年初至今跌44.53%，过去60日涨6.14%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711101024a443a7f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711101024a443a7f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FGEN","BK4505"],"gpt_icon":0},{"id":"2550625762","title":"珐博进盘中异动 早盘股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550625762","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550625762?lang=zh_cn&edition=full","pubTime":"2025-07-10 21:47","pubTimestamp":1752155252,"startTime":"0","endTime":"0","summary":"北京时间2025年07月10日21时47分，珐博进股票出现波动，股价快速拉升5.01%。截至发稿，该股报6.50美元/股，成交量6915股，换手率0.17%，振幅4.28%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。珐博进股票所在的生物技术行业中，整体跌幅为0.04%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710214732953d8673&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710214732953d8673&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","BK4505","CGTX","FGEN"],"gpt_icon":0},{"id":"2550695130","title":"珐博进7月9日成交额为54.46万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550695130","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550695130?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:07","pubTimestamp":1752113239,"startTime":"0","endTime":"0","summary":"美东时间2025年7月9日，珐博进成交额为54.46万美元，成交额较昨日增加235.53%，当日成交量为9.11万股。珐博进于2025年7月9日涨10.14%，报6.19美元，该股过去5个交易日涨17.46%，年初至今跌53.28%，过去60日跌4.77%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710100725a6a080b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710100725a6a080b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","FGEN"],"gpt_icon":0},{"id":"2550503891","title":"珐博进7月8日成交额为16.23万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550503891","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550503891?lang=zh_cn&edition=full","pubTime":"2025-07-09 10:05","pubTimestamp":1752026731,"startTime":"0","endTime":"0","summary":"美东时间2025年7月8日，珐博进成交额为16.23万美元，成交额较昨日减少20.73%，当日成交量为2.91万股。珐博进于2025年7月8日涨4.66%，报5.62美元，该股过去5个交易日涨6.04%，年初至今跌57.58%，过去60日跌14.52%。该公司的绝大部分收入来自欧洲，其次是日本。迄今为止，珐博进几乎所有的收入都来自其合作协议。珐博进寻求具有研究、开发和营销能力以及其他资源的合作伙伴，以增强公司推进候选产品的能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709100541a69e3ba5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709100541a69e3ba5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FGEN","BK4505"],"gpt_icon":0},{"id":"2550520835","title":"珐博进盘中异动 下午盘股价大涨5.21%报5.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550520835","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550520835?lang=zh_cn&edition=full","pubTime":"2025-07-09 02:41","pubTimestamp":1752000075,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日02时41分，珐博进股票出现异动，股价大幅拉升5.21%。截至发稿，该股报5.65美元/股，成交量1.8091万股，换手率0.45%，振幅4.24%。最近的财报数据显示，该股实现营业收入2.74百万美元，净利润-16.77百万美元，每股收益1.15美元，毛利2.16百万美元，市盈率-2.24倍。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。珐博进股票所在的生物技术行业中，整体涨幅为1.07%。迄今为止，珐博进几乎所有的收入都来自其合作协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709024116979ea923&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709024116979ea923&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FGEN","BK4505"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fibrogen.com","stockEarnings":[{"period":"1week","weight":0.0263},{"period":"1month","weight":0.0058},{"period":"3month","weight":-0.2396},{"period":"6month","weight":0.4957},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.3503}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Fibrogen, Inc.于1993年在美国特拉华州注册成立。该公司是一家生物制药公司，专注于癌症生物学和贫血前沿领域的新疗法开发。该公司正在开发FG-3246，这是一种潜在的靶向CD46的first-in-class抗体药物偶联物，用于治疗转移性去势抵抗性前列腺癌和潜在的其他癌症。该计划还包括FG-3180的开发，这是一种相关的CD46靶向正电子发射断层扫描生物标志物和显像剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.727273,"avgChangeRate":0.196681},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.032668},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.060681},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.133734},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.039352},{"month":6,"riseRate":0.636364,"avgChangeRate":-0.001658},{"month":7,"riseRate":0.545455,"avgChangeRate":-0.034699},{"month":8,"riseRate":0.363636,"avgChangeRate":0.01162},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.009378},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.070226},{"month":11,"riseRate":0.727273,"avgChangeRate":0.07854},{"month":12,"riseRate":0.636364,"avgChangeRate":0.094223}],"exchange":"NASDAQ","name":"FibroGen, Inc","nameEN":"FibroGen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FibroGen, Inc(FGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供FibroGen, Inc(FGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"FibroGen, Inc,FGEN,FibroGen, Inc股票,FibroGen, Inc股票老虎,FibroGen, Inc股票老虎国际,FibroGen, Inc行情,FibroGen, Inc股票行情,FibroGen, Inc股价,FibroGen, Inc股市,FibroGen, Inc股票价格,FibroGen, Inc股票交易,FibroGen, Inc股票购买,FibroGen, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FibroGen, Inc(FGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供FibroGen, Inc(FGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}